Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Gains from Investment Securities (2020 - 2025)

Journey Medical (DERM) has disclosed Gains from Investment Securities for 6 consecutive years, with $2.4 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Gains from Investment Securities rose 180.69% year-over-year to $2.4 million, compared with a TTM value of $118000.0 through Sep 2025, down 32.57%, and an annual FY2024 reading of $2.5 million, down 10.76% over the prior year.
  • Gains from Investment Securities was $2.4 million for Q1 2025 at Journey Medical, up from $21000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.4 million in Q1 2025 and bottomed at $1000.0 in Q4 2021.
  • Average Gains from Investment Securities over 5 years is $393131.5, with a median of $78000.0 recorded in 2023.
  • The sharpest move saw Gains from Investment Securities soared 14800.0% in 2022, then tumbled 98.96% in 2023.
  • Year by year, Gains from Investment Securities stood at $1000.0 in 2021, then skyrocketed by 14800.0% to $149000.0 in 2022, then tumbled by 35.57% to $96000.0 in 2023, then tumbled by 78.12% to $21000.0 in 2024, then skyrocketed by 11438.82% to $2.4 million in 2025.
  • Business Quant data shows Gains from Investment Securities for DERM at $2.4 million in Q1 2025, $21000.0 in Q4 2024, and $1000.0 in Q3 2024.